The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EBMT 2016 | Assessment of response in multiple myeloma: next steps
Bruno Paiva, PhD, from the University of Navarra, Pamplona, Spain discusses open questions in the assessment of response in multiple myeloma (MM). According to Dr Paiva, we should see overall response rates of around 70-80% in a relapsed/refractory setting and complete remission (CR) rates of around 20-30%. In future, a deep response, including minimal residual disease (MRD) negativity, may be a goal for fit relapsed/refractory patients. Other areas that require research are biomarkers and ultra chemotherapy-resistant MRD cells.
Recorded at the 2016 Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) in Valencia, Spain.
